China NMPA Product Recall - Puerarin for Injection

On November 15, 2010, the Shandong Provincial Food and Drug Administration, operating under the National Medical Products Administration (NMPA) framework, mandated Ruiyang Pharmaceutical Co., Ltd. to recall its Puerarin for Injection, specifically batch number 09112006. This regulatory action was initiated after recent supervisory inspections by food and drug authorities uncovered significant quality problems with the aforementioned pharmaceutical product. The primary issue identified was substandard quality of the Puerarin for Injection, posing a potential risk to medication safety and effectiveness for patients. To address this, Ruiyang Pharmaceutical Co., Ltd. is required to promptly retrieve all affected units of batch 09112006 from circulation. The Shandong Provincial Food and Drug Administration has also declared that it will handle the matter in accordance with legal stipulations, implying further investigation and potential enforcement measures to ensure compliance and public health protection. This directive underscores the regulatory body's commitment to maintaining stringent pharmaceutical quality control.